CUMBERLAND PHARMACEUTICALS INC
Close on Oct 19, 2026
- Market cap
- $100.38M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 3, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 4, 2026 | During market hours | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | During market hours | $9.10M | $-0.22 | $-0.13 |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 3, 2026 | During market hours | $13.70M | $-0.09 | $-0.01 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | During market hours | $8.30M | $-0.13 | $-0.06 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | During market hours | $10.80M | $-0.05 | $0.02 |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | During market hours | $11.71M | $0.08 | $0.16 |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 4, 2025 | During market hours | $10.40M | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | During market hours | $9.10M | $-0.11 | $-0.02 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 5, 2024 | During market hours | – | – | – |
Press releases
Announcements Cumberland Pharmaceuticals filed with the SEC
COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE
Other events · EX-99.1 to Form 8-K
Focus on Rare Disease Pipeline
Material agreement · Agreement terminated · Acquisition or disposition completed · Executive or director change · Other events · EX-99.1 to Form 8-K
UNAUDITED PRO FORMA FINANCIAL INFORMATION
Material agreement · Agreement terminated · Acquisition or disposition completed · Executive or director change · Other events · EX-99.2 to Form 8-K
Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE
Results of operations · EX-99.1 to Form 8-K
to Integrate Commercial Business with Apotex
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
31.1% FOURTH QUARTER 2025 REVENUE GROWTH
Results of operations · EX-99.1 to Form 8-K
Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program
Other events · EX-99.1 to Form 8-K
Cumberland ended the quarter with approximately $66 million in total assets, $40 million in liabilities and $26 million of shareholders’ equity.
Results of operations · EX-99.1 to Form 8-K
CUMBERLAND PHARMACEUTICALS ANNOUNCES THE ADDITION OF AN
Other events · EX-99.1 to Form 8-K
Cumberland ended the quarter with approximately $68 million in total assets, $40 million in liabilities and $28 million of shareholders’ equity.
Results of operations · EX-99.1 to Form 8-K
Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025
Results of operations · EX-99.1 to Form 8-K
at MDA Clinical & Scientific Conference
Other events · EX-99.1 to Form 8-K
11.6% Fourth Quarter 2024 Revenue Growth
Results of operations · EX-99.1 to Form 8-K
VIBATIV ® RECEIVES MARKETING APPROVAL IN CHINA
Other events · EX-99.1 to Form 8-K
Breakthrough Results from the Phase 2 FIGHT DMD Trial
Other events · EX-99.1 to Form 8-K
FDA APPROVES ACETADOTE ® sNDA
Other events · EX-99.1 to Form 8-K
ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS
Other events · EX-99.1 to Form 8-K
Cumberland Pharmaceuticals Reports Third Quarter 2024
Results of operations · EX-99.1 to Form 8-K
New Study Compares Caldolor ® (ibuprofen injection) to ketorolac
Other events · EX-99.1 to Form 8-K
NASHVILLE, TENNESSEE ( Tuesday , August 6, 2024 ) – Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced significantly improved financial results and a favorable overall company performance for the second quarter of 2024 .
Results of operations · EX-99.1 to Form 8-K
Cumberland Pharmaceuticals Reports First Quarter 2024
Results of operations · EX-99.1 to Form 8-K
2023 highlights include expanded FDA approval and new study publications
Results of operations · EX-99.1 to Form 8-K
Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
NEW VIBATIV ® PEDIATRIC PUBLICATION
Other events · EX-99.1 to Form 8-K
NASHVILLE, TENNESSEE (Tuesday, August 8, 2023) - Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutical company, today announced significantly improved financial results and a favorable overall company performance for the second quarter of 2023.
Results of operations · EX-99.1 to Form 8-K
CALDOLOR ® NOW FDA APPROVED
Other events · EX-99.1 to Form 8-K
Cumberland Pharmaceuticals Reports First Quarter 2023
Results of operations · EX-99.1 to Form 8-K